Scilex Holding Company Successfully Closes $17 Million Registered Direct Offering in 2024
Scilex Holding Company Announces Successful Completion of Registered Direct Offering Company Overview Scilex Holding Company, traded on Nasdaq as SCLX, is a forward-thinking organization dedicated to acquiring, developing, and commercializing treatments for neurodegenerative and cardiometabolic diseases. Additionally, the company focuses on providing non-opioid pain management products for both acute and chronic pain. Offering Details On…